Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jun 15;15(6):418. doi: 10.1038/s41419-024-06814-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A, B The nuclear vs. cytoplasmic localization of LINC00152 in MCF-7 (A) and T47D (B) Par and TamR cells. MALAT1 and DANCR were used as controls for nuclear and cytoplasmic RNAs, respectively. C Percent cell viability inhibition in MCF-7.TamR cells expressing shLINC00152 upon treatment with tamoxifen. D GSEA analysis showing the ferroptosis-related genes enriched in low LINC00152-expressing ER+ breast cancer patients treated with endocrine therapy from GSE87411. E Pearson correlation analysis of LINC00152 expression with ferroptosis score in ER+ patients from GSE58644. F, G The levels of ferroptosis score before and after endocrine therapy in sensitive (F) and resistant (G) ER+ patients from GSE87411. H Percentage cell viability inhibition in shLINC00152-expressing MCF-7.TamR cells treated with tamoxifen with or without 0.1 µM of liproxstatin-1 (Lipro). I Relative intracellular Fe²⁺ levels in shCtrl or shLINC00152-expressing MCF-7.TamR cells that were treated with 7.5 µM tamoxifen for 1.5 h. J Lipid peroxidation assay in T47D.TamR cells transfected with siLINC00152 (siLINC) in combination with tamoxifen, showing fold change of lipid peroxidation. Cumene was used as a positive control. K Western blot analysis of the negative regulators of ferroptosis, xCT, GPX4, and FTH1 in MCF-7.TamR cells expressing shLINC00152 and treated with tamoxifen. Actin is used as a loading control in all Western blots unless stated otherwise. L Percentage cell viability inhibition in shLINC00152-expressing MCF-7.TamR cells transfected with GPX4 or xCT open reading frame (ORF). M, N Percentage cell viability inhibition in MCF-7.TamR (M) and T47D.TamR (N) cells treated with tamoxifen alone or in combination with 3 or 5 µM RSL3. Data are presented as mean values ± standard deviation (SD). P-values for (D) were calculated using the GSEA software (Broad Institute) while others were calculated with the paired (cell viability) or unpaired (others), two-tailed Student’s t-test. *P < 0.05, **P < 0.01, n.s. not significant.